Skip to content
Bomb Report – Lifestyle
Author:
Global Down Syndrome Foundation
Celebrities Terrell Davis, John C. McGinley & Caterina Scorsone Join the Largest Down Syndrome Fundraiser in the World
July 30, 2026
Crnic Institute Landmark Research Paves the Way for Personalized Medicine in Down Syndrome
July 23, 2026
Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
July 23, 2026
U.S. House Unanimously Passes DeOndra Dixon INCLUDE Project Act – A Historic Victory for Down Syndrome Research
July 21, 2026
What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
June 25, 2026
Denver Teen with Down Syndrome Stars in Award-Winning Film Debuting on Netflix During Father’s Day Weekend
June 11, 2026
Zepbound (tirzepatide) and Shaquille O’Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable
June 10, 2026
Lilly’s oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
June 9, 2026
Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
June 8, 2026
Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
June 8, 2026
1
2
3
Next Page
→